Review



sm1 71  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    MedChemExpress sm1 71
    a Study design of in vitro and in vivo experiments. b Western blot analysis of phosphorylated and total Mek1 and Erk in Trp53 −/− –ATII organoids. NC negative control group, WT group overexpressing WT MAP2K1 , MT group overexpressing MAP2K1 ΔE102−I103 . c Morphological changes (top), H&E staining (second row), and IHC of EpCAM (third row) and TTF-1 (bottom) in Trp53 −/− –ATII organoids after 5 days of culture. Scale bar, 50 µm. d Relative viability of organoids on days 1, 3, and 5. n = 3 biological replicates. e Relative organoid area of organoids on day 5. f – h Growth curve ( f ), end point illustration ( g , scale bar, 1 cm), and tumor weight ( h ) of Trp53 −/− ( n = 4), Trp53 −/− ; MAP2K1 WT ( n = 4), and Trp53 −/− ; MAP2K1 MT ( n = 4) allografts. i H&E staining and IHC of TTF-1, KRT7, and EpCAM of the Trp53 −/− ; MAP2K1 MT organoid allograft at the experiment endpoint (day 48). Scale bar, 50 µm. j Efficacy of <t>SM1-71,</t> an inhibitor of MAP2K1, in treating MAP2K1 MT , MAP2K1 WT , and negative-control Ba/F3 cells. * p < 0.05, ** p < 0.01, *** p < 0.001.
    Sm1 71, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sm1+71/SM1-71/pmc12689645-402-0-1
    Average 93 stars, based on 1 article reviews
    sm1 71 - by Bioz Stars, 2026-09
    93/100 stars

    Images

    1) Product Images from "Genomic and transcriptomic dynamics in the stepwise progression of lung adenocarcinoma"

    Article Title: Genomic and transcriptomic dynamics in the stepwise progression of lung adenocarcinoma

    Journal: Cell Research

    doi: 10.1038/s41422-025-01200-w

    a Study design of in vitro and in vivo experiments. b Western blot analysis of phosphorylated and total Mek1 and Erk in Trp53 −/− –ATII organoids. NC negative control group, WT group overexpressing WT MAP2K1 , MT group overexpressing MAP2K1 ΔE102−I103 . c Morphological changes (top), H&E staining (second row), and IHC of EpCAM (third row) and TTF-1 (bottom) in Trp53 −/− –ATII organoids after 5 days of culture. Scale bar, 50 µm. d Relative viability of organoids on days 1, 3, and 5. n = 3 biological replicates. e Relative organoid area of organoids on day 5. f – h Growth curve ( f ), end point illustration ( g , scale bar, 1 cm), and tumor weight ( h ) of Trp53 −/− ( n = 4), Trp53 −/− ; MAP2K1 WT ( n = 4), and Trp53 −/− ; MAP2K1 MT ( n = 4) allografts. i H&E staining and IHC of TTF-1, KRT7, and EpCAM of the Trp53 −/− ; MAP2K1 MT organoid allograft at the experiment endpoint (day 48). Scale bar, 50 µm. j Efficacy of SM1-71, an inhibitor of MAP2K1, in treating MAP2K1 MT , MAP2K1 WT , and negative-control Ba/F3 cells. * p < 0.05, ** p < 0.01, *** p < 0.001.
    Figure Legend Snippet: a Study design of in vitro and in vivo experiments. b Western blot analysis of phosphorylated and total Mek1 and Erk in Trp53 −/− –ATII organoids. NC negative control group, WT group overexpressing WT MAP2K1 , MT group overexpressing MAP2K1 ΔE102−I103 . c Morphological changes (top), H&E staining (second row), and IHC of EpCAM (third row) and TTF-1 (bottom) in Trp53 −/− –ATII organoids after 5 days of culture. Scale bar, 50 µm. d Relative viability of organoids on days 1, 3, and 5. n = 3 biological replicates. e Relative organoid area of organoids on day 5. f – h Growth curve ( f ), end point illustration ( g , scale bar, 1 cm), and tumor weight ( h ) of Trp53 −/− ( n = 4), Trp53 −/− ; MAP2K1 WT ( n = 4), and Trp53 −/− ; MAP2K1 MT ( n = 4) allografts. i H&E staining and IHC of TTF-1, KRT7, and EpCAM of the Trp53 −/− ; MAP2K1 MT organoid allograft at the experiment endpoint (day 48). Scale bar, 50 µm. j Efficacy of SM1-71, an inhibitor of MAP2K1, in treating MAP2K1 MT , MAP2K1 WT , and negative-control Ba/F3 cells. * p < 0.05, ** p < 0.01, *** p < 0.001.

    Techniques Used: In Vitro, In Vivo, Western Blot, Negative Control, Staining

    Related Articles

    In Vitro:

    Article Title: Genomic and transcriptomic dynamics in the stepwise progression of lung adenocarcinoma
    Article Snippet: Fluorescence signals were detected using 530/30-nm (GFP) and 610/20-nm (mCherry) filters.Fluorescence signals were detected using 530/30-nm (GFP) and 610/20-nm (mCherry) filters.. SM1-71 (MCE, Cat# HY-136848) was used as a MAP2K1 inhibitor.

    Article Title: Genomic and transcriptomic dynamics in the stepwise progression of lung adenocarcinoma.
    Article Snippet: Fluorescence signals were detected using 530/30-nm (GFP) and 610/20-nm (mCherry) filters.Fluorescence signals were detected using 530/30-nm (GFP) and 610/20-nm (mCherry) filters.. SM1-71 (MCE, Cat HY-136848) was used as a MAP2K1 inhibitor.

    In Vivo:

    Article Title: Genomic and transcriptomic dynamics in the stepwise progression of lung adenocarcinoma
    Article Snippet: Fluorescence signals were detected using 530/30-nm (GFP) and 610/20-nm (mCherry) filters.Fluorescence signals were detected using 530/30-nm (GFP) and 610/20-nm (mCherry) filters.. SM1-71 (MCE, Cat# HY-136848) was used as a MAP2K1 inhibitor.

    Article Title: Genomic and transcriptomic dynamics in the stepwise progression of lung adenocarcinoma.
    Article Snippet: Fluorescence signals were detected using 530/30-nm (GFP) and 610/20-nm (mCherry) filters.Fluorescence signals were detected using 530/30-nm (GFP) and 610/20-nm (mCherry) filters.. SM1-71 (MCE, Cat HY-136848) was used as a MAP2K1 inhibitor.

    Western Blot:

    Article Title: Genomic and transcriptomic dynamics in the stepwise progression of lung adenocarcinoma
    Article Snippet: Fluorescence signals were detected using 530/30-nm (GFP) and 610/20-nm (mCherry) filters.Fluorescence signals were detected using 530/30-nm (GFP) and 610/20-nm (mCherry) filters.. SM1-71 (MCE, Cat# HY-136848) was used as a MAP2K1 inhibitor.

    Article Title: Genomic and transcriptomic dynamics in the stepwise progression of lung adenocarcinoma.
    Article Snippet: Fluorescence signals were detected using 530/30-nm (GFP) and 610/20-nm (mCherry) filters.Fluorescence signals were detected using 530/30-nm (GFP) and 610/20-nm (mCherry) filters.. SM1-71 (MCE, Cat HY-136848) was used as a MAP2K1 inhibitor.

    Negative Control:

    Article Title: Genomic and transcriptomic dynamics in the stepwise progression of lung adenocarcinoma
    Article Snippet: Fluorescence signals were detected using 530/30-nm (GFP) and 610/20-nm (mCherry) filters.Fluorescence signals were detected using 530/30-nm (GFP) and 610/20-nm (mCherry) filters.. SM1-71 (MCE, Cat# HY-136848) was used as a MAP2K1 inhibitor.

    Article Title: Genomic and transcriptomic dynamics in the stepwise progression of lung adenocarcinoma.
    Article Snippet: Fluorescence signals were detected using 530/30-nm (GFP) and 610/20-nm (mCherry) filters.Fluorescence signals were detected using 530/30-nm (GFP) and 610/20-nm (mCherry) filters.. SM1-71 (MCE, Cat HY-136848) was used as a MAP2K1 inhibitor.

    Staining:

    Article Title: Genomic and transcriptomic dynamics in the stepwise progression of lung adenocarcinoma
    Article Snippet: Fluorescence signals were detected using 530/30-nm (GFP) and 610/20-nm (mCherry) filters.Fluorescence signals were detected using 530/30-nm (GFP) and 610/20-nm (mCherry) filters.. SM1-71 (MCE, Cat# HY-136848) was used as a MAP2K1 inhibitor.

    Article Title: Genomic and transcriptomic dynamics in the stepwise progression of lung adenocarcinoma.
    Article Snippet: Fluorescence signals were detected using 530/30-nm (GFP) and 610/20-nm (mCherry) filters.Fluorescence signals were detected using 530/30-nm (GFP) and 610/20-nm (mCherry) filters.. SM1-71 (MCE, Cat HY-136848) was used as a MAP2K1 inhibitor.



    Similar Products

    sm1 71  (MedChemExpress)
    93
    MedChemExpress sm1 71
    a Study design of in vitro and in vivo experiments. b Western blot analysis of phosphorylated and total Mek1 and Erk in Trp53 −/− –ATII organoids. NC negative control group, WT group overexpressing WT MAP2K1 , MT group overexpressing MAP2K1 ΔE102−I103 . c Morphological changes (top), H&E staining (second row), and IHC of EpCAM (third row) and TTF-1 (bottom) in Trp53 −/− –ATII organoids after 5 days of culture. Scale bar, 50 µm. d Relative viability of organoids on days 1, 3, and 5. n = 3 biological replicates. e Relative organoid area of organoids on day 5. f – h Growth curve ( f ), end point illustration ( g , scale bar, 1 cm), and tumor weight ( h ) of Trp53 −/− ( n = 4), Trp53 −/− ; MAP2K1 WT ( n = 4), and Trp53 −/− ; MAP2K1 MT ( n = 4) allografts. i H&E staining and IHC of TTF-1, KRT7, and EpCAM of the Trp53 −/− ; MAP2K1 MT organoid allograft at the experiment endpoint (day 48). Scale bar, 50 µm. j Efficacy of <t>SM1-71,</t> an inhibitor of MAP2K1, in treating MAP2K1 MT , MAP2K1 WT , and negative-control Ba/F3 cells. * p < 0.05, ** p < 0.01, *** p < 0.001.
    Sm1 71, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sm1+71/SM1-71/pmc12689645-402-0-1
    Average 93 stars, based on 1 article reviews
    sm1 71 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    a Study design of in vitro and in vivo experiments. b Western blot analysis of phosphorylated and total Mek1 and Erk in Trp53 −/− –ATII organoids. NC negative control group, WT group overexpressing WT MAP2K1 , MT group overexpressing MAP2K1 ΔE102−I103 . c Morphological changes (top), H&E staining (second row), and IHC of EpCAM (third row) and TTF-1 (bottom) in Trp53 −/− –ATII organoids after 5 days of culture. Scale bar, 50 µm. d Relative viability of organoids on days 1, 3, and 5. n = 3 biological replicates. e Relative organoid area of organoids on day 5. f – h Growth curve ( f ), end point illustration ( g , scale bar, 1 cm), and tumor weight ( h ) of Trp53 −/− ( n = 4), Trp53 −/− ; MAP2K1 WT ( n = 4), and Trp53 −/− ; MAP2K1 MT ( n = 4) allografts. i H&E staining and IHC of TTF-1, KRT7, and EpCAM of the Trp53 −/− ; MAP2K1 MT organoid allograft at the experiment endpoint (day 48). Scale bar, 50 µm. j Efficacy of SM1-71, an inhibitor of MAP2K1, in treating MAP2K1 MT , MAP2K1 WT , and negative-control Ba/F3 cells. * p < 0.05, ** p < 0.01, *** p < 0.001.

    Journal: Cell Research

    Article Title: Genomic and transcriptomic dynamics in the stepwise progression of lung adenocarcinoma

    doi: 10.1038/s41422-025-01200-w

    Figure Lengend Snippet: a Study design of in vitro and in vivo experiments. b Western blot analysis of phosphorylated and total Mek1 and Erk in Trp53 −/− –ATII organoids. NC negative control group, WT group overexpressing WT MAP2K1 , MT group overexpressing MAP2K1 ΔE102−I103 . c Morphological changes (top), H&E staining (second row), and IHC of EpCAM (third row) and TTF-1 (bottom) in Trp53 −/− –ATII organoids after 5 days of culture. Scale bar, 50 µm. d Relative viability of organoids on days 1, 3, and 5. n = 3 biological replicates. e Relative organoid area of organoids on day 5. f – h Growth curve ( f ), end point illustration ( g , scale bar, 1 cm), and tumor weight ( h ) of Trp53 −/− ( n = 4), Trp53 −/− ; MAP2K1 WT ( n = 4), and Trp53 −/− ; MAP2K1 MT ( n = 4) allografts. i H&E staining and IHC of TTF-1, KRT7, and EpCAM of the Trp53 −/− ; MAP2K1 MT organoid allograft at the experiment endpoint (day 48). Scale bar, 50 µm. j Efficacy of SM1-71, an inhibitor of MAP2K1, in treating MAP2K1 MT , MAP2K1 WT , and negative-control Ba/F3 cells. * p < 0.05, ** p < 0.01, *** p < 0.001.

    Article Snippet: SM1-71 (MCE, Cat# HY-136848) was used as a MAP2K1 inhibitor.

    Techniques: In Vitro, In Vivo, Western Blot, Negative Control, Staining